External-Beam Radiotherapy in the Management of Carcinoma of the Prostate

Zlotecki, Robert A.

doi:10.1177/107327480100800605

Cited by 5 publications

(4 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Such combination high-dose radiation therapy was introduced in the 1990s when PSA testing demonstrated poor biochemical cure rates with conventional irradiation. 10 Our patient's prolonged latency period of 15 years is consistent with reports of other radiation-induced malignancies which have mean latency periods of 5-15 years. 11 As high-dose irradiation is increasingly used to treat prostate cancer, it would be unsurprising if the incidence of secondary radiation-induced malignancies were to rise.…”

Section: Discussionsupporting

confidence: 90%

Prostatic carcinosarcoma 15 years after combined external beam radiation and brachytherapy for prostatic adenocarcinoma: a case report

Tseng

Sevilla

Moul

et al. 2006

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

A 65-year-old man with a history of combined pelvic external beam radiation therapy (EBRT) and brachytherapy for prostatic adenocarcinoma 15 years prior underwent total pelvic exenteration for presumed rectal sarcoma with prostatic invasion. Pathology revealed carcinosarcoma of prostatic origin. This patient exhibited the longest reported interval between initial presentation with prostatic adenocarcinoma and development of carcinosarcoma. This case is also the first reported case of prostatic carcinosarcoma occurring after combined EBRT and brachytherapy. The increasing use of such combination high-dose radiation therapy may potentially lead to an increased incidence of secondary malignancies such as prostatic carcinosarcoma in the future.

show abstract

Section: Discussionsupporting

confidence: 90%

Prostatic carcinosarcoma 15 years after combined external beam radiation and brachytherapy for prostatic adenocarcinoma: a case report

Tseng

Sevilla

Moul

et al. 2006

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

show abstract

“…1 The European Organization for Research and Treatment of Cancer (EORTC) was first to report on a statistically significant advantage of cancer and overall survival in patients who received adjuvant androgen deprivation therapy together with an external-beam RT. 2 Although the expression, distribution and the significance of steroid receptors in prostate biology is generally well-recognized, [3][4][5][6][7] the evaluation of the status of steroid receptors in the prostate after RT for prostate carcinoma has not received much attention.…”

mentioning

confidence: 99%

Differential expression of steroid receptors in prostate tissues before and after radiation therapy for prostatic adenocarcinoma

Torlakovic

Lilleby²,

Berner

et al. 2005

Intl Journal of Cancer

View full text Add to dashboard Cite

The expression, distribution and the role of steroid receptors in benign and malignant untreated prostate tissues is well recognized, however, the status of steroid receptors in prostate after radiotherapy (RT) for adenocarcinoma has not yet been studied fully. Immunohistochemical evaluation of androgen receptor (AR), estrogen receptor-alpha (ER-a), estrogen receptor-beta (ER-b), and progesterone receptor (PR) was carried out in prostate needle biopsies obtained before and after radiotherapy from 60 patients with adenocarcinoma. The ER-b transcripts were also studied by RT-PCR in LNCaP prostate carcinoma cell line before and 24 hr after c-irradiation at 0.5 Gy and 8.0 Gy. Significantly higher level of ER-b expression was found in post-radiation samples of prostate adenocarcinoma and benign epithelium. After RT, all steroid receptors were upregulated in prostatic stroma. Tumor AR expression did not change significantly. Although a positive association between AR and ER-b expression was observed in pretreatment prostate adenocarcinoma, it was lost after RT suggesting that these 2 steroid receptors respond differently to RT. High levels of pretreatment tumor ER-b were associated with local recurrence after RT and decreased biochemical recurrence-free survival (p 5 0.028). LNCaP cell line that expressed no ER-b mRNA before c-irradiation, clearly expressed ER-b mRNA 24 hr after 0.5 Gy and 8.0 Gy. Upregulation of all steroid receptors in the prostate stroma and upregulation of ER-b in the tumor epithelium after RT, may represent a protective tissue response to radiation-induced tissue injury. Although stromal AR was doubled after RT, the tumor and benign epithelium expression of AR seemed resistant to change by RT. ' 2005 Wiley-Liss, Inc.

show abstract

“…For patients with intermediate or high-risk patients, doses between 75-80 Gy are better. Several clinical studies have emphasized the improvement of biochemical response and control with use of highly conformal doses-the escalation of the same 12,13,14 .…”

Section: Current Radiotherapy Techniquementioning

confidence: 99%

“…The percents of local relapse within a postoperative period of 10 to 15 years ranges from 20-60%, depending on the method of detecting and reporting 12 . The management of margin positive disease is still contraversial.…”

Section: Radical Prostatectomy Plus Radiotherapymentioning

confidence: 99%

Radio therapy in prostate cancer treatment

Radošević-Jelić¹,

Stojanović²,

Popov³

2005

ACTA CHIR IUG

View full text Add to dashboard Cite

Prostate cancer is a complex disease, with many controversial aspects of management in almost all stages of disease. The natural history of this tumor is variable and is influenced by multiple prognostic factors. Radical prostatectomy and radiotherapy are standard treatment options for disease limited to the prostate. The data in literature does not provide clear- cut evidence for the superiority of any treatment. Neo- adjuvant or adjuvant hormonal therapy improves local control and survival in locally advanced disease. The patients treated with radiotherapy would have a relatively long life expectancy, not great risk factors for radiation toxicity and a preference for radiotherapy. The advantages of radiotherapy are that it has a significant potential for cure, it is well tolerated in the majority of men especially when the modern techniques of conformal radiotherapy and intensity modulated therapy are used and it is non-invasive therapeutic options with no anesthesia risk. Expected complications like radiation cystitis, impotence and proctitis are registered in about 1% of patients.

show abstract

External-Beam Radiotherapy in the Management of Carcinoma of the Prostate

Abstract: Background: External-beam radiotherapy (EBRT) has been used in the treatment of adenocarcinoma of the

Cited by 5 publications

References 33 publications

Prostatic carcinosarcoma 15 years after combined external beam radiation and brachytherapy for prostatic adenocarcinoma: a case report

Prostatic carcinosarcoma 15 years after combined external beam radiation and brachytherapy for prostatic adenocarcinoma: a case report

Differential expression of steroid receptors in prostate tissues before and after radiation therapy for prostatic adenocarcinoma

Radio therapy in prostate cancer treatment

Contact Info

Product

Resources

About